The role of miRNA and lncRNA in gastric cancer

Hao, Ning-Bo; He, Yang; Li, Xiaoqin; Wang, Kai; Wang, Rui-Ling

doi:10.18632/oncotarget.19197

Cited by 201 publications

(131 citation statements)

References 96 publications

Supporting

Mentioning

129

Contrasting

Order By: Relevance

“…Noncoding RNAs can be grouped into lncRNAs (.200 nt in length) and small noncoding RNAs (#200 nt in length), including miRNAs. Mounting evidence has shown that deregulated miRNAs and lncRNAs function as key regulators in the initiation and progression of multiple cancers, including OC, via many different pathways (44)(45)(46). Our present study, for the first time, revealed a novel ceRNA model, in which the MALAT1/miR-211/PHF19 regulatory axis participate in the pathogenesis of OC.…”

Section: Discussionmentioning

confidence: 51%

miR‐211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma

et al. 2018

View full text Add to dashboard Cite

Accumulating evidence has indicated that microRNAs (miRNAs) play an important role in the occurrence and progression of ovarian cancer (OC). However, the function of miRNAs implicated in OC remains unclear. This study investigated the potential role of miR-211 in OC. Gene Expression Omnibus database analysis indicated that miR-211 expression was significantly down-regulated in OC tissues compared with normal specimens. In addition, miR-211 overexpression apparently inhibited proliferation, migration, xenograft growth, and induced apoptosis in HEY-T30 and SKOV3 cells. Moreover, PHF19, a component of the polycomb group of proteins, was found to be a direct target of miR-211 based on the luciferase reporter assay and Western blot analysis. Consistently, survival analysis indicated that high PHF19 expression was associated with shorter survival time in patients with OC. Importantly, silence of PHF19 reduced proliferation, induced cell cycle arrest, promoted apoptosis, suppressed migration, and inhibited xenograft growth in SKOV3 cells. Restoration of PHF19 expression markedly reversed the inhibitory effect of miR-211 on OC. Moreover, our results indicate that the long noncoding RNA MALAT1 could sponge miR-211 as a competing endogenous RNA and potentially up-regulate PHF19 expression, thus facilitating the OC progression. These findings suggest that the MALAT1/miR-211/PHF19 axis may act as a key mediator in OC and provide new insight into the prevention of this disease.-Tao, F., Tian, X., Ruan, S., Shen, M., Zhang, Z. miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma.

show abstract

Section: Discussionmentioning

confidence: 51%

miR‐211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…To overcome such problems, new technology such as miRNA, lncRNA which considered potential biomarker or to regulate GC progression at the transcript or transcript level has also been developed [54] . Although these researches are still in the preclinical stage, they have been expected as a solution for the recent problems.…”

Section: Discussionmentioning

confidence: 99%

Update on targeted therapy and immune therapy for gastric cancer, 2018

Kiyozumi¹,

Iwatsuki²,

Yamashita³

et al. 2018

JCMT

View full text Add to dashboard Cite

Gastric cancer (GC) remains one of the most common cancers and serious health problems worldwide. For unresectable or metastatic advanced gastric cancer, chemotherapy treatment is first selected. Although chemotherapy has improved survival in patients with advanced gastric cancer (AGC), the prognosis of these patients remains poor. In recent years, some therapies targeting biological molecules have been reported to prolong the survival of patients with AGC. Since trastuzumab, a monoclonal antibody that targets HER2, was established as standard therapy for unresectable GC in

show abstract

“…A combination of cytokeratin 19 and 20 from CTCs can detect GC with sensitivity and specificity of 87.5% and 94.7%, respectively, suggesting their use in the diagnosis of GC [71]. Recently, miRNAs are emerging as biomarkers in diagnosis and treatment of cancers in general and GC in particular [72,73]. A number of miRNAs from peripheral mononuclear cells could be used as surrogate markers to highlight GC patients.…”

Section: Diagnostic Potential Of Ctc In Gcmentioning

confidence: 99%

Emerging Role of Circulating Tumor Cells in Gastric Cancer

Huong

Gurshaney

Bình

et al. 2020

Cancers

View full text Add to dashboard Cite

With over 1 million incidence cases and more than 780,000 deaths in 2018, gastric cancer (GC) was ranked as the 5th most common cancer and the 3rd leading cause of cancer deaths worldwide. Though several biomarkers, including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4), have been identified, their diagnostic accuracies were modest. Circulating tumor cells (CTCs), cells derived from tumors and present in body fluids, have recently emerged as promising biomarkers, diagnostically and prognostically, of cancers, including GC. In this review, we present the landscape of CTCs from migration, to the presence in circulation, biologic properties, and morphologic heterogeneities. We evaluated clinical implications of CTCs in GC patients, including diagnosis, prognosis, and therapeutic management, as well as their application in immunotherapy. On the one hand, major challenges in using CTCs in GC were analyzed, from the differences of cut-off values of CTC positivity, to techniques used for sampling, storage conditions, and CTC molecular markers, as well as the unavailability of relevant enrichment and detection techniques. On the other hand, we discussed future perspectives of using CTCs in GC management and research, including the use of circulating tumor microembolies; of CTC checkpoint blockade in immunotherapy; and of organoid models. Despite the fact that there are remaining challenges in techniques, CTCs have potential as novel biomarkers and/or a non-invasive method for diagnostics, prognostics, and treatment monitoring of GC, particularly in the era of precision medicine.

show abstract

The role of miRNA and lncRNA in gastric cancer

Cited by 201 publications

References 96 publications

miR‐211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma

miR‐211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma

Update on targeted therapy and immune therapy for gastric cancer, 2018

Emerging Role of Circulating Tumor Cells in Gastric Cancer

Contact Info

Product

Resources

About